RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail targets tough lung cancer in early trial
Disease control OngoingThis early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer that has spread or come back. The goal is to find the safest dose of the targeted drug ensartinib when given with standard chemotherapy (carboplatin, pemetrexed) a…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:26 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study is for people with advanced non-small cell lung cancer that has come back or spread. It tests a combination of two drugs: trametinib, which blocks cancer cell growth, and pembrolizumab, which helps the immune system attack cancer. The goal is to see if this combination…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:24 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control OngoingThis early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The goal is to find the safest dose and see if the combination can shrink tumors or slow the diseas…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:24 UTC
-
New drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-stage trial tests whether adding necitumumab to osimertinib is safe and tolerable for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous targeted therapy. About 138 participants will receive the combination to find the best dos…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:22 UTC
-
New combo therapy aims to keep early lung cancer from returning
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New drug combo aims to boost immune system against tough lung cancer
Disease control OngoingThis study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab works better than standard treatments for people with advanced non-small cell lung cancer that has already been treated with other immunotherapies. N-803 activates natural killer cells…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study tested a combination of two drugs, trametinib and docetaxel, in 60 people with advanced KRAS-mutant non-small cell lung cancer that had worsened after one or two prior treatments. The goal was to see if the combination could shrink tumors. Participants received both dr…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New combo attack on advanced lung cancer shows early promise
Disease control OngoingThis early trial tests whether adding surgery or radiation to the targeted drug brigatinib can better control advanced ALK-positive non-small cell lung cancer. About 35 people whose cancer has spread or returned will receive both treatments. The main goal is to check safety and s…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has worsened after previous treatment. The main goal is to find the safest dose and understand side effects. About 36…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New drug combo targets tough lung cancer in small early trial
Disease control OngoingThis early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. Researchers are testing a combination of two drugs—brigatinib and bevacizumab—to see what dose is …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Can adding surgery or radiation to a targeted pill stop lung cancer longer?
Disease control OngoingThis study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 173 adults with stage IIIB or IV non-small cell lung cancer that has a specific EGFR mutatio…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tests two drugs, erlotinib and cabozantinib, given alone or together in people with advanced non-small cell lung cancer that does not have a certain gene change (EGFR mutation). The goal is to see if the combination works better than either drug alone to slow cancer gr…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Precision radiation boosts tumor attack in advanced lung cancer trial
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the dose to nearby healthy organs standard, is safe and effective for people with stage II to III non-small cell lung cancer. It uses advanced imaging to guide either photon (IMRT) or pro…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Cord blood cells engineered to fight lung cancer in early trial
Disease control OngoingThis early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Hope for lung cancer patients: drug combo may beat chemo after immunotherapy fails
Disease control OngoingThis study tests whether a combination of two drugs (ramucirumab and pembrolizumab) works better than standard chemotherapy for people with advanced or returning non-small cell lung cancer who have already tried immunotherapy. About 838 participants will be randomly assigned to o…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Experimental combo aims to boost Radiation's punch against returning lung tumors
Disease control OngoingThis early-phase study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be removed by surgery. The main goals are to find the safest dose…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
Could adding durvalumab early beat lung cancer?
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation (and continuing it afterward) helps people with stage 3 lung cancer that can't be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagnosed…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:00 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs—atezolizumab (an immunotherapy that helps the immune system attack cancer) and cobimetinib (a targeted therapy that blocks cancer growth signals)—can shrink tumors or slow disease in people with advanced non-small cell lung cancer that…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Vitamin a derivative joins immunotherapy in fight against advanced lung cancer
Disease control OngoingThis early-stage trial tests a combination of all-trans retinoic acid (ATRA), a drug made from vitamin A, and atezolizumab, an immunotherapy, in 18 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New targeted therapy shows promise for rare lung cancer subtype
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in people with a specific type of advanced or recurrent non-small cell lung cancer that has a RET gene fusion. The drug works by blocking enzymes that help cancer cells grow. About 124 participants will receive the treatment…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Blood test may tame Chemo's nerve pain
Knowledge-focused TerminatedThis study looks at whether regularly measuring the amount of paclitaxel (a chemotherapy drug) in the blood can help doctors give the right dose to kill cancer while limiting nerve damage. About 22 adults with various solid tumors (like lung, breast, or ovarian cancer) will have …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated May 26, 2026 04:15 UTC